OBJECTIVE: Recent evidence indicates that the apolipoprotein E (ApoE) epsilon4 allele is a risk factor for developing Alzheimer's disease. It has also been proposed that it is associated with increased counts of amyloid plaques and neurofibrillary tangles that in turn are neuropathological hallmarks initially appearing in the medial temporal lobe structures in Alzheimer's disease. In this study, the effect of the ApoE epsilon4 allele on the volume of the entorhinal cortex was evaluated in vivo. METHODS: The volume of the entorhinal cortex was measured on MR images using a recently designed histology based protocol in 16 patients with Alzheimer's disease with ApoE epsilon4 (mean age 70.4 (SD 9.9)), 11 patients with Alzheimer's disease without ApoE epsilon4 (mean age 69.1 (SD7.1)), and in 31 healthy age and sex matched normal controls (72.2 (SD 3.9)). The patients met the NINCDS-ADRDA criteria for probable Alzheimer's disease and were in mild to moderate stages of the disease. MRI was performed with a 1.5 Tesla Magnetom and a 3D technique permitting the reconstruction of 2.0 mm thick contiguous slices perpendicular to the axis of the anterior-posterior commissure. RESULTS: The patients with Alzheimer's disease without the ApoE epsilon4 allele had atrophy in the entorhinal cortex, the volume was reduced by 27% compared with control subjects. However, the most prominent shrinkage (45%) in the entorhinal cortex was seen in patients with Alzheimer's disease with the ApoE epsilon4 allele (p=0.0001). The effect of epsilon4 on the entorhinal cortex volume was especially prominent in female patients with Alzheimer's disease compared to male patients with Alzheimer's disease (p=0.014). Additionally, patients with the ApoE epsilon4 allele had inferior performance in verbal and visual memory functions than those without the allele CONCLUSIONS: Volumetric MRI measurements disclose that ApoE epsilon4 is associated with the degree of atrophy in the entorhinal cortex in early Alzheimer's disease, this effect being especially prominent in female patients with Alzheimer's disease.
OBJECTIVE: Recent evidence indicates that the apolipoprotein E (ApoE) epsilon4 allele is a risk factor for developing Alzheimer's disease. It has also been proposed that it is associated with increased counts of amyloid plaques and neurofibrillary tangles that in turn are neuropathological hallmarks initially appearing in the medial temporal lobe structures in Alzheimer's disease. In this study, the effect of the ApoEepsilon4 allele on the volume of the entorhinal cortex was evaluated in vivo. METHODS: The volume of the entorhinal cortex was measured on MR images using a recently designed histology based protocol in 16 patients with Alzheimer's disease with ApoEepsilon4 (mean age 70.4 (SD 9.9)), 11 patients with Alzheimer's disease without ApoEepsilon4 (mean age 69.1 (SD7.1)), and in 31 healthy age and sex matched normal controls (72.2 (SD 3.9)). The patients met the NINCDS-ADRDA criteria for probable Alzheimer's disease and were in mild to moderate stages of the disease. MRI was performed with a 1.5 Tesla Magnetom and a 3D technique permitting the reconstruction of 2.0 mm thick contiguous slices perpendicular to the axis of the anterior-posterior commissure. RESULTS: The patients with Alzheimer's disease without the ApoEepsilon4 allele had atrophy in the entorhinal cortex, the volume was reduced by 27% compared with control subjects. However, the most prominent shrinkage (45%) in the entorhinal cortex was seen in patients with Alzheimer's disease with the ApoEepsilon4 allele (p=0.0001). The effect of epsilon4 on the entorhinal cortex volume was especially prominent in female patients with Alzheimer's disease compared to male patients with Alzheimer's disease (p=0.014). Additionally, patients with the ApoEepsilon4 allele had inferior performance in verbal and visual memory functions than those without the allele CONCLUSIONS: Volumetric MRI measurements disclose that ApoEepsilon4 is associated with the degree of atrophy in the entorhinal cortex in early Alzheimer's disease, this effect being especially prominent in female patients with Alzheimer's disease.
Authors: M J Ignatius; P J Gebicke-Härter; J H Skene; J W Schilling; K H Weisgraber; R W Mahley; E M Shooter Journal: Proc Natl Acad Sci U S A Date: 1986-02 Impact factor: 11.205
Authors: Klaus H Fritzsche; Bram Stieltjes; Sarah Schlindwein; Thomas van Bruggen; Marco Essig; Hans-Peter Meinzer Journal: Int J Comput Assist Radiol Surg Date: 2010-05-04 Impact factor: 2.924
Authors: May A Beydoun; Adel Boueiz; Marwan S Abougergi; Melissa H Kitner-Triolo; Hind A Beydoun; Susan M Resnick; Richard O'Brien; Alan B Zonderman Journal: Neurobiol Aging Date: 2010-07-08 Impact factor: 4.673
Authors: Yi-Yu Chou; Natasha Leporé; Greig I de Zubicaray; Owen T Carmichael; James T Becker; Arthur W Toga; Paul M Thompson Journal: Neuroimage Date: 2007-12-08 Impact factor: 6.556
Authors: Xue Hua; Alex D Leow; Neelroop Parikshak; Suh Lee; Ming-Chang Chiang; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson Journal: Neuroimage Date: 2008-07-22 Impact factor: 6.556
Authors: Lajos Csincsik; Thomas J MacGillivray; Erin Flynn; Enrico Pellegrini; Giorgos Papanastasiou; Neda Barzegar-Befroei; Adrienne Csutak; Alan C Bird; Craig W Ritchie; Tunde Peto; Imre Lengyel Journal: Ophthalmic Res Date: 2018-04-05 Impact factor: 2.892
Authors: Nanthia A Suthana; Allison Krupa; Markus Donix; Alison Burggren; Arne D Ekstrom; Michael Jones; Linda M Ercoli; Karen J Miller; Prabha Siddarth; Gary W Small; Susan Y Bookheimer Journal: Neuroimage Date: 2009-12-18 Impact factor: 6.556
Authors: Christine Fennema-Notestine; Linda K McEvoy; Donald J Hagler; Mark W Jacobson; Anders M Dale Journal: Behav Neurol Date: 2009 Impact factor: 3.342